摘要
心梗(MI)后心脏病理改变复杂,涉及心肌细胞、内皮细胞、成纤维细胞、巨噬细胞等多种细胞及分子机制。采用具有多靶点作用效应的中药进行治疗能够发挥良好的心脏保护作用,但多组分剂中药复杂的作用机制一直未被充分的阐明,限制了中药的广泛使用。单细胞转录组测序(scRNA-seq)技术具有超高通量,可在单次实验中完成不同处理条件下几百种药物的单细胞转录组的分析,识别出不同的细胞及细胞亚型对药物治疗的响应差异。利用scRNA-seq技术能够了解从急性缺血事件到慢性心脏瘢痕形成过程中,心脏重构确切细胞和分子机制。将scRNA-seq技术应用于MI后中药心脏保护作用机制研究,能够加快中药研发的进程,同时能够获得更丰富、更全面、更准确的信息,有助于理解中药基于复杂网络而发挥药效的作用机制。本文通过总结目前中药心脏保护作用机制研究进展,介绍scRNA-seq技术的发展概况及其在MI中的应用现况,以此来探讨scRNA-seq在MI后中药心脏保护作用机制研究中可能的应用前景,为中药现代化研究提供思路。
The pathological changes of the heart after myocardial infarction(MI) are complex,involving multiple molecular mechanisms and various cells, such as myocardial cells, endothelial cells,fibroblasts,and macrophages. With multiple targets,Chinese medicine demonstrates ideal cardioprotective effect. However, the complex mechanism of multi-component Chinese medicine formulas has not been elucidated,thus limiting the further application. The high-throughput single-cell RNA sequencing(scRNA-seq)technology offers single-cell transcriptome analysis of hundreds of drugs under different processing conditions in a single experiment and identifies the differences in the response of different cells and cell subtypes to drug treatment. scRNA-seq technology helps us to understand the exact cellular and molecular mechanisms of cardiac remodeling from acute ischemic events to chronic cardiac scarring. The application of scRNA-seq to studying the cardioprotective mechanism of Chinese medicine after MI can boost the development of Chinese medicine,help obtain richer,more accurate and comprehensive information. It can give us a clear insight into the mechanism of Chinese medicine based on complex network. In this study,we summarized the research on cardioprotective mechanism of Chinese medicine and introduced the development of scRNA-seq technology and the application to MI research. Finally, we explored the possible application prospects of scRNA-seq in the research on cardioprotective mechanism of Chinese medicine after MI,hoping to provide ideas for the modernization of Chinese medicine.
作者
彭菊琴
任钧国
高铸烨
PENG Ju-qin;REN Jun-guo;GAO Zhu-ye(Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2022年第5期242-249,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家“重大新药创制”科技重大专项(2019ZX09201005-002-006,2017ZX09301018)
中国中医科学院科技创新工程重大攻关项目(CI2021A00920)
北京市中医药科技发展项目(JJ-2020-79)
世界中医药学会联合会项目(WFCMS2019002)。
关键词
单细胞转录组测序
心梗
中药
机制研究
single-cell RNA sequencing
myocardial infarction
Chinese medicine
mechanism research
